Jeffrey Abbey, a pharma executive and lawyer, has joined ImmunOs Therapeutics AG of Switzerland as chief operating officer as the company prepares for clinical trials of its biologics for cancer and autoimmune diseases. Mr Abbey is a consultant who has previously served as chief executive of Novadip Biosciences SA, a Belgian cell therapy company, and CEO of the former Argos Therapeutics Inc of the US. His appointment coincides with ImmunOs’ creation of a clinical advisory board composed of four cancer experts. They are: Andrew Scott of Austin Health in Australia; Dmitriy Zamarin of the Memorial Sloan Kettering Cancer Center in the US; Dirk Jäger of the National Center for Tumour Diseases in Heidelberg, Germany; and Jeffrey Bockman of Cello Health BioConsulting Inc of the US.
ImmunOs Therapeutics announced the appointments on 1 September 2021.
Copyright 2021 Evernow Publishing Ltd.